Understand the source comparison
Peter Attia Peptides: Comparison of Therapeutic Classes
BPC-157 Angiogenesis, collagen synthesis, gut barrier repair Promising rodent data, minimal human trials Potential utility under physician oversight with imaging confirmation High risk/reward ratio—use only with informed consent about unknown long-term safety
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Angiogenesis, collagen synthesis, gut barrier repair
- Promising rodent data, minimal human trials
- Potential utility under physician oversight with imaging confirmation
- High risk/reward ratio—use only with informed consent about unknown long-term safety
- Thymosin Beta-4/TB-500
- Actin sequestering, cell migration, immune modulation
- Phase 2 trials in cardiac repair, limited in other indications
- Mechanistically sound but requires individualized dosing and biomarker tracking
- Moderate evidence base—TB-500 (synthetic) not identical to endogenous TB-4
- Growth Hormone Secretagogues (CJC-1295, Ipamorelin)
- GH/IGF-1 axis stimulation via ghrelin mimicry
- Established GH response, insufficient long-term safety data
- High-risk without baseline IGF-1, glucose, and cancer screening
- Dangerous without pre-intervention metabolic and oncology assessment
- Oral 'Systemic' Peptides
- Claimed gastric stability for systemic absorption
- No credible pharmacokinetic data supporting systemic bioavailability
- Pharmacologically implausible—digestive enzymes degrade peptide bonds
- Marketing fiction—subcutaneous/IM injection required for systemic effect